Classes | Virtual Medical Academy

Viewing 1102 results

Diabetes

Introducing Mounjaro: A Once-Weekly, First-in-Class GIP and GLP-1 Receptor Agonist

By :

Lilly Saudi Arabia

Neurology

Barriers and benefits to a timely diagnosis

By :

Prof.Dr.Liz Coulthard

Neurology

Tracking the pathology of Alzheimer's disease

By :

Prof.Sylvan Lehmann

Neurology

State-of-the-art biomarker toolkit

By :

Dr. Fortea and Prof. Shi

Neurology

Disclosing biomarker results+B2:B5

By :

Prof. Dr. Kenjiro & Prof. Dr. Jens

Oncology

Jaypirca: A Novel BTK Inhibitor With a Well-Tolerated Safety Profile

By :

Dr.Chaves

Oncology

How Does Jaypirca Work? The Science Explained

By :

Dr Alan Skarbnik

Diabetes

Supporting Patients with Obesity Through Comprehensive Treatment

By :

Prof.W.Timothy Garvey

Diabetes

Proposed actions of GIP and GLP1 receptor agonist in human

By :

Prof.Rachel Batterham

Diabetes

Potential Impact of Weight Reduction on Obesity-Related Complications

By :

Prof.W.Timothy Garvey

Oncology

Sparking discussions on Jaypirca – Efficacy results

By :

Dr Julio Chavez

Oncology

Sparking Discussions about Jaypirca Appropriate Patients

By :

Dr Alan Skarbnik

About Us

Support

Technical Requirements

VMA Team

Partner

Introducing Mounjaro: A Once-Weekly, First-in-Class GIP and GLP-1 Receptor Agonist

Barriers and benefits to a timely diagnosis

Tracking the pathology of Alzheimer's disease

State-of-the-art biomarker toolkit

Disclosing biomarker results+B2:B5

Jaypirca: A Novel BTK Inhibitor With a Well-Tolerated Safety Profile

How Does Jaypirca Work? The Science Explained

Supporting Patients with Obesity Through Comprehensive Treatment

Proposed actions of GIP and GLP1 receptor agonist in human

Potential Impact of Weight Reduction on Obesity-Related Complications

Sparking discussions on Jaypirca – Efficacy results

Sparking Discussions about Jaypirca Appropriate Patients

Call Center 920008161

[email protected]